SCD and fatty liver disease: In addition, CD47ASO treatment reduced hepatic steatosis as demonstrated by reduced liver Oil Red O staining and liver triglyceride measurement (Fig. 3A,B), which was associated with reduced expression of lipid synthesis genes including FAS, ACC and SCD1 (Fig. 3C).